ArticleAmerican journal of respiratory and critical care medicine2005
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
Article in American journal of respiratory and critical care medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Pooled it
- An Overview of Various Rifampicin Analogs againstMedicinal chemistry (Shariqah (United Arab Emirates)) · 2024Review
- One Size Fits All? Not inFrontiers in cellular and infection microbiology · 2021Review
- Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection.Antimicrobial agents and chemotherapy · 2019Article
- Preclinical Efficacy Testing of New Drug Candidates.Microbiology spectrum · 2017Review
- Latent tuberculosis infection: myths, models, and molecular mechanisms.Microbiology and molecular biology reviews : MMBR · 2014Review
- Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis.Antimicrobial agents and chemotherapy · 2014Article
- Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis.Human vaccines & immunotherapeutics · 2013Article
- Chemotherapeutic interventions against tuberculosis.Pharmaceuticals (Basel, Switzerland) · 2012Article
- Targeting persisters for tuberculosis control.Antimicrobial agents and chemotherapy · 2012Review
- Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis.PloS one · 2012Article
- Current management options for latent tuberculosis: a review.Infection and drug resistance · 2012Article
- Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.American journal of respiratory and critical care medicine · 2011Article
- New therapeutic approach for latent tuberculosis infection.Lung India : official organ of Indian Chest Society · 2011Article
- Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.PloS one · 2011Article
- New approaches in the diagnosis and treatment of latent tuberculosis infection.Respiratory research · 2010Review
- Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.Antimicrobial agents and chemotherapy · 2010Article
- The use of anti-tuberculosis therapy for latent TB infection.Infection and drug resistance · 2010Article
- Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.American journal of respiratory and critical care medicine · 2009Article
- Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.Antimicrobial agents and chemotherapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
rationalePriorities for developing improved regimens for treatment of latent tuberculosis (TB) infection include (1) developing shorter and/or more intermittently administered regimens that are easier to supervise and (2) developing and evaluating regimens that are active against multidrug-resistant organisms. OBJECTIVES AND
methodsBy using a previously validated murine model that involves immunizing mice with Mycobacterium bovis bacillus Calmette-Guérin to augment host immunity before infection with virulent Mycobacterium tuberculosis, we evaluated new treatment regimens including rifapentine and moxifloxacin, and assessed the potential of the Mycobacterium leprae heat shock protein-65 DNA vaccine to augment the activity of moxifloxacin. MEASUREMENTS: Quantitative spleen colony-forming unit counts, and the proportion of mice with culture-positive relapse after treatment, were determined. MAIN
resultsThree-month, once-weekly regimens of rifapentine combined with either isoniazid or moxifloxacin were as active as daily isoniazid for 6-9 mo. Six-month daily combinations of moxifloxacin with pyrazinamide, ethionamide, or ethambutol were more active than pyrazinamide plus ethambutol, a regimen recommended for latent TB infection after exposure to multidrug-resistant TB. The combination of moxifloxacin with the experimental nitroimidazopyran PA-824 was especially active. Finally, the heat shock protein-65 DNA vaccine had no effect on colony-forming unit counts when given alone, but augmented the bactericidal activity of moxifloxacin.
conclusionsTogether, these findings suggest that rifapentine, moxifloxacin, and, perhaps, therapeutic DNA vaccination have the potential to improve on the current treatment of latent TB infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.